Anti-Müllerian hormone: Predictor of premature ovarian insufficiency in Egyptian women with autoimmune thyroiditis

Rashad, Nearmeen M.; Moafy, Hala; Saleh, Hend S; Amin, Abdelaziz I.; Gomaa, A. M.

doi:10.1016/j.mefs.2018.01.012

Cited by 6 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Как уже хорошо известно, менопауза связана с гормоночувствительными сопутствующими заболеваниями -раком (молочной железы, эндометрия), сердечно-сосудистыми заболеваниями, остеопорозом и т. д. [37]. Соответственно, необходимо понимание механизма аутоиммунных заболеваний [38].…”

Section: Discussionunclassified

Autoimmune thyroiditis in different age groups and subjects of reproductive age in Adzhariya population

Tchelidze

Glonti

Baratashvili

et al. 2022

Akušerstvo, ginekologiâ i reprodukciâ

View full text Add to dashboard Cite

Introduction. Autoimmune thyroiditis (AIT) is the most prevalent among the autoimmune pathologies and multifactorial thyroid diseases; accordingly, remaining a pressing issue for investigation.Aim: to study AIT profile in different age groups of the female population in the western region of Georgia – Adzhariya.Materials and Methods. A prospective comparative study in parallel groups was carried out. There were examined 405 samples of venous blood obtained at «Health» Clinic from women of two groups: group 1 – 159 patients with AIT, group 2 (control) – 246 women without AIT. Blood samples were collected between the years 2017 and 2020. There were analyzed serum antibodies against thyroperoxidase (TPOAb), thyroid stimulating hormone (TSH) as well as level of free thyroxine (FT4) by using enzyme immunoassay.Results. Patients with AIT from different age groups vs. control group were found to have decreased level of FT4, but increased amount of TSH and TPOAb. At the reproductive age (18–45 years), a significant increase in the level of TSH was found (6.12 times) compared with the control group (p < 0.0001). The level of FT4 and TSH in AIT women aged 51 to 60 years was 0.7880 ± 0.3584 ng/ml and 4.754 ± 2.433 U/ml that significantly differed from those in the control group – 1.314 ± 0.4044 ng/ml (p < 0.0001) and 2.276 ± 1.409 U/ml (p < 0.0001), respectively.Conclusion. AIT occurs in women of all age groups, but is more common in women aged 51 to 60 years. In a number of cases, TPOAb was detected in the control group, which, apparently, is associated with increased intake of dietary iodized salt since 2005 in Georgia (the adoption of the law on universal salt iodization). A significant increase in the level of TSH, in AIT women aged 18–45 years, strongly suggests to perform diagnostics of and screening for AIT not only in females of menopausal period, but also in reproductive age.

show abstract

Section: Discussionunclassified

Autoimmune thyroiditis in different age groups and subjects of reproductive age in Adzhariya population

Tchelidze

Glonti

Baratashvili

et al. 2022

Akušerstvo, ginekologiâ i reprodukciâ

View full text Add to dashboard Cite

show abstract

“…Primary ovarian insufficiency (POI) is a reproductive endocrine disorder in women that is the cause of ovarian follicle dysfunction. Its symptoms are usually amenorrhea for more than 4 months and overproduction of FSH (> 40 IU/L) [55] in women before 40 years of age. This hormonal deficiency increases the chance of cardiovascular disease, metabolic syndrome, and osteoporosis as well as impaired reproductive capacity [56].…”

Section: Primary Ovarian Insufficiencymentioning

confidence: 99%

“…In women with POI, the AMH concentration is undetectable [59]. This is why AMH levels are considered a predictor of POI among women, especially those which have autoimmune thyroiditis [55].…”

Section: Primary Ovarian Insufficiencymentioning

confidence: 99%

The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility

Bedenk

Vrtačnik-Bokal

Virant‐Klun

2019

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose In this review, the current knowledge on anti-Müllerian hormone (AMH) is presented, concerning its value in disease and IVF treatment as well as in terms of its prospective clinical use. Methods AMH is becoming the most appropriate biomarker for the ovarian reserve measured predominantly for assisted reproductive treatment (ART) patients in comparison to the currently used antral follicle count (AFC). However, this is not the only way AMH measurements can be used in the clinics. Because of this, we reviewed the current literature for the use of AMH in current or prospective clinical practice. Results We found that AMH has a high predictive value in assessing the ovarian reserve, which can lead to a better efficiency of in vitro fertilization (IVF) procedures. It has a high potential to be developed as a staple diagnostic marker of ovarian disease, especially for ovarian cancers and even as a possible treatment tool for certain cancers. It could potentially be used to prevent oocyte loss due to chemo-or radiotherapy. Conclusion AMH is an important hormone especially in women reproductive organs and is currently seen as the best biomarker for a multitude of uses in reproductive medicine. Currently, the biggest issue lies in the lack of international standardization of AMH. However, it is encouraging to see that there is interest in AMH in the form of research on its action and use in reproductive medicine.

show abstract

“…It is considered to be one of the best biomarkers for the evaluation of a patient’s ovarian reserve [ 13 – 15 ], response to controlled ovarian stimulation [ 16 ] and the outcome of IVF, although the results of the latter vary [ 17 , 18 ]. It is also predicted that AMH can become a powerful tool for the diagnosis of certain ovarian illnesses, such as PCOS [ 19 , 20 ], primary ovarian insufficiency (POI) [ 21 ], premature menopause [ 22 ] and gynaecological tumours [ 23 – 25 ]. The key receptor for AMH is anti-Müllerian hormone receptor 2 (AMHR2), which is expressed in testicular Sertoli [ 26 – 28 ] and Leydig cells [ 28 – 30 ], ovarian theca [ 28 , 31 ] and granulosa cells [ 26 – 28 ], as well as in the prostate [ 32 ], breasts [ 33 ] and endometrium [ 34 ].…”

Section: Introductionmentioning

confidence: 99%

Recombinant anti-Müllerian hormone in the maturation medium improves the in vitro maturation of human immature (GV) oocytes after controlled ovarian hormonal stimulation

Bedenk

Režen

Ramuta

et al. 2022

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Background In vitro maturation (IVM) of oocytes is a laboratory method that allows the maturation of immature (GV) oocytes retrieved from patients enrolled in the in vitro fertilization (IVF) programme. However, this method is still sparsely researched and used in clinical practice, leading to suboptimal clinical results. Anti-Müllerian hormone (AMH) is an important hormone with known effects on human ovaries, especially on follicles (follicular cells) during folliculogenesis. In contrast, the effect of AMH on the human oocyte itself is unknown. Therefore, we wanted to determine whether human oocytes express AMH receptor 2 (AMHR2) for this hormone. Recombinant AMH was added to the IVM medium to determine whether it affected oocyte maturation. Methods In total, 247 human oocytes (171 immature and 76 mature) were collected from patients enrolled in the intracytoplasmic sperm injection (ICSI) programme who were aged 20 to 43 years and underwent a short antagonist protocol of ovarian stimulation. The expression of AMHR2 protein and AMHR2 gene was analysed in immature and mature oocytes. Additionally, maturation of GV oocytes was performed in vitro in different maturation media with or without added AMH to evaluate the effect of AMH on the oocyte maturation rate. Results Immunocytochemistry and confocal microscopy revealed that AMHR2 protein is expressed in both immature and mature human oocytes. AMHR2 was expressed in a spotted pattern throughout the whole oocyte. The IVM procedure revealed that AMH in maturation medium improved GV oocyte maturation in vitro, as all oocytes were successfully matured in maturation medium containing recombinant AMH only. Furthermore, antagonism between AMH and follicle-stimulating hormone (FSH) during the maturation process was observed, with fewer oocytes maturing when both AMH and FSH were added to the maturation medium. Finally, AMHR2 gene expression was found in immature and in vitro matured oocytes but absent in mature oocytes. Conclusions The positive AMHR2 protein and AMHR2 gene expression in human oocytes shows that AMH could directly act on human oocytes. This was further functionally confirmed by the IVM procedure. These findings suggest the potential clinical application of recombinant AMH to improve IVM of human oocytes in the future.

show abstract

Anti-Müllerian hormone: Predictor of premature ovarian insufficiency in Egyptian women with autoimmune thyroiditis

Cited by 6 publications

References 31 publications

Autoimmune thyroiditis in different age groups and subjects of reproductive age in Adzhariya population

Autoimmune thyroiditis in different age groups and subjects of reproductive age in Adzhariya population

The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility

Recombinant anti-Müllerian hormone in the maturation medium improves the in vitro maturation of human immature (GV) oocytes after controlled ovarian hormonal stimulation

Contact Info

Product

Resources

About